Valtecne (VLT) Q1 2026 TU earnings summary

Executive summary

• Consolidated quarterly revenues surpassed €10 million for the first time, reaching €10.3 million as of March 31, 2026, up 9.6% year-over-year.

• Growth was driven by the Medical business line, especially orthopaedic and dental segments, and a strong recovery in the Industrial business line.

• Stand-alone revenues rose to €8.8 million, a 12.1% increase compared to the same period in 2025.

Financial highlights

• Medical business line revenues grew 7.1% year-over-year to €7.5 million, maintaining about 75% of total consolidated revenues.

• Industrial business line revenues increased 16.9% year-over-year to €2.7 million, reflecting market recovery.

• Stand-alone Medical revenues rose 10.4% to €6.6 million; Industrial revenues up 17.3% to €2.2 million.

• As of December 31, 2025, production value was €37.3 million and adjusted EBITDA was €9.7 million, with an EBITDA margin of 26.0%.

Outlook and guidance

• Continued investments in digitalisation, production process innovation, and workforce expansion are planned to support growth.

• Commercial development activities are being intensified to expand growth opportunities, leveraging new senior advisory expertise.